Bangalore, Feb 08, 2010: ClinTec International, a full service contract research organisation (CRO), has announced that it has achieved organic growth with a 45 percent increase in global sales revenues over the last twelve months. The company has also expanded its client base and signed new contracts with 11 of the world’s top 25 pharmaceutical firms.
Dr Rabinder Buttar, Founder, President and CEO of ClinTec International, said, “Our strong financial performance, achieved during a difficult economic climate, is linked to our established track record of managing activities in a fast and flexible manner. Whilst other CROs suffered project delays or cancellations, ClinTec forged ahead developing innovative services in 17 new countries, employing 115 new staff in the process. Looking ahead to 2010 and 2011, we comfortably project a continuation of this substantial growth trend.”
“The launch of our Cairo office in October 2009 was one of the high points of the year. Apart from providing our global pharmaceutical associates with access to new patient populations, ClinTec Cairo cements our reputation as the major CRO in the Middle East and North Africa (MENA) region,” said Dr Buttar.
ClinTec has played a key role in 2009 in facilitating complex restructuring programs for global pharma, who are searching for innovative ways to optimize their R&D efforts. The shift of research delivery from West to East is an area in which ClinTec is clearly able to offer solution for using a blend between flexible resource solutions and off-shore project delivery.
| 
Comment on this article
